ReGelTec Enrolls 1st Patient in the HYDRAFIL®-D Study
Jun 18, 2025 7:05 AM Eastern Daylight Time
BALTIMORE–(BUSINESS WIRE)–ReGelTec Inc., a company developing a percutaneous hydrogel implant for the treatment of chronic low back pain caused by degenerative disc disease, announced it has treated the first patient in its HYDRAFIL-D FDA investigational device exemption (IDE) clinical trial for its HYDRAFIL® System for disc augmentation. The patient was enrolled by Kas Amirdelfan, M.D., an interventional pain physician and founding member of Boomerang Healthcare, Inc. in Walnut Creek, Calif. The HYDRAFIL System is an outpatient procedure offering interventional pain physicians and patients a new treatment designed to reduce pain and improve daily function without the need for an invasive surgery
Additional News from this Article:
- Med-Tech Insights – June 24, 2025 ReGelTec announces first patient treated in U.S. IDE clinical trial for HYDRAFIL system
- OrthoWorld – June 24, 2025 ReGelTec Commences Clinical Trial for HYDRAFIL to Treat Low Back Pain
- Backer’s Spine Review – June 18, 2025 – First spine patient treated in Hydrafil IDE trial
- Ortho Spine News – June 18, 2025 – ReGelTec Announces First Patient Treated in U.S. IDE Clinical Trial for HYDRAFIL to Treat Chronic Low Back Pain
- BioSpace – June 18, 2025 – ReGelTec Announces First Patient Treated in U.S. IDE Clinical Trial for HYDRAFIL System to Treat Chronic Low Back Pain
ABOUT REGELTEC, INC:
ReGelTec, Inc. is a clinical stage medical device company commercializing HYDRAFIL®, a percutaneous treatment for low back pain due to degenerative disc disease. The company was formed when a team of chemical engineers with extensive experience in polymer science partnered with a cross-functional team of medical device professionals with multiple successful startup exits. Once approved, the HYDRAFIL® System will offer patients suffering from chronic back pain due to degenerative disc disease a minimally invasive treatment option beyond traditional conservative care. HYDRAFIL® is an investigational device, limited by United States law to investigational use.
